在FDA不良事件报告系统 (FAERS) 数据库中对蒂尔泽帕提德的真实数据分析
1Department of Pathology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.
Frontiers in pharmacology
|June 24, 2024
概括
提尔泽帕提德用于体重管理,但这项研究发现了意想不到的不良药物反应,如错误的剂量和注射部位问题. 对于使用这种药物的患者来说,全面的安全监测至关重要.
科学领域:
- 药监和药物安全研究.
- 临床药理学和治疗学.
背景情况:
- 提尔泽帕提德适用于肥胖或超重的成年人的慢性体重管理.
- 它作为一种双重的依赖葡萄糖的胰岛素型多 (GIP) 和类似葡萄糖-1 (GLP-1) 受体激动剂.
- 需要对与蒂尔泽帕提德相关的不良事件进行彻底评估.
研究的目的:
- 检测和分析与蒂尔泽帕提德相关的药物不良反应 (ADR).
- 通过药监数据识别预期和意外的安全信号.
- 为了提高蒂尔泽帕提德的临床药物安全性.
主要方法:
- 从2022年第一季度到2023年第三季度利用了FDA不良事件报告系统 (FAERS) 数据库.
- 使用不成比例分析,包括ROR,PRR,BCPNN和EBGM,以检测潜在的ADR信号.
- 使用医学监管活动词典 (MedDRA) 进行分类的已识别的副作用.
主要成果:
- 分析了1,904,481个病例报告,在8个器官系统类别中确定了46个提尔泽帕提德诱导的副作用.
- 确认了预期的副作用,如胃食道逆流症和吐.
- 发现了意想不到的显著的副作用,包括错误的剂量,注射部位出血和食欲增加.
结论:
- 该研究提供了关于监测和管理与蒂尔泽帕提德相关的不良药物反应的见解.
- 意想不到的重大不良事件信号需要仔细考虑患者的安全性.
- 加强监测可以改善蒂尔泽帕提德的安全临床使用.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
06:05The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
1.3K
相关概念视频
Pharmacovigilance
821
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
821
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Hazard Ratio
111
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
111
